Aloracetam

Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,[4] but was never marketed.

Aloracetam

Clinical data
ATC code	none
Legal status
Legal status	US: Unscheduled Not FDA approved
Identifiers
IUPAC name N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
CAS Number	119610-26-3^Y
PubChem CID	178134
ChemSpider	155069^Y
UNII	U0RKZ75D0T
ChEMBL	ChEMBL2104637
CompTox Dashboard (EPA)	DTXSID10152524
Chemical and physical data
Formula	C11H16N2O2
Molar mass	208.261 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=C(N1CCNC(=O)C)C)C=O
InChI InChI=1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15)^Y Key:ZUQSGZULKDDMEW-UHFFFAOYSA-N^Y
(verify)

See also

• Piracetam

References

1. "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015.
2. Charles F. George (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
3. C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
4. Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.